Rasha Aboelhassan, Senior Oncology Consultant at Nasser Institute Hospital, shared posts on ESMO GI 2026 commenting on sessions with:
“Happening Now:
Jenny Seligmann
Great presentation and professional discussion by MDT panel for MSI-H rectal cancer.”
“Happening Now:
Maria Reig
Explaining: How to deal with uncertainty, complexity if HCC?
How to deal with emotional and subjectivity during MDT?
Very informative excellent application of real world clinical practice.
Thanks for all panellists for the great discussion.”
Jens Ricks, Joseph P Erinjiri, Bruno Sangro
“EMERALD-3 and EMERALD-1 panel discussion. Two clinical trials with different results,
Patients in both EMERALD-1 and EMERALD-3 trials shared the same foundational eligibility: they had unresectable, embolization-eligible hepatocellular carcinoma (HCC).
But in real-world:
Should we combine immunotherapy with anti- angiogenic therapy (bevacizumab or Lenvatinib) and with TACE for those patients?
Thanks for panellists who had this challenging discussion: Jens Ricks, Joseph P Erinjiri, Bruno Sangro.”
“Who is the luckiest patient with colon cancer?
This question came to my mind during ESMO GI 2026, and this slide provided a compelling answer.
The luckiest patient is not simply the one with a driver mutation – but the one whose tumor harbors an actionable driver alteration with an approved targeted therapy.
Every new biomarker discovered and every new targeted treatment approved represents another opportunity to change a patient’s journey. Behind each advance are years of dedicated research by investigators committed to turning scientific discoveries into meaningful clinical benefit.
Precision oncology is no longer just about understanding the biology of cancer – it’s about ensuring that every patient has access to the right biomarker testing and the right treatment at the right time.
Every new target offers new hope.”
“A great wrap-up of the hepatocellular carcinoma (HCC) clinical trials presented during the final day of ESMO GI 2026 .
The added insights are valuable perspective, helping to connect the evidence with its practical implications for patient care.”
Other articles featuring Rasha Aboelhassan on OncoDaily.
